KR20180130544A - 위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법 - Google Patents

위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법 Download PDF

Info

Publication number
KR20180130544A
KR20180130544A KR1020187031360A KR20187031360A KR20180130544A KR 20180130544 A KR20180130544 A KR 20180130544A KR 1020187031360 A KR1020187031360 A KR 1020187031360A KR 20187031360 A KR20187031360 A KR 20187031360A KR 20180130544 A KR20180130544 A KR 20180130544A
Authority
KR
South Korea
Prior art keywords
composition
thc
cbd
cannabis
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187031360A
Other languages
English (en)
Korean (ko)
Inventor
리히 바-레브 슈라이더
Original Assignee
투 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 투 파마슈티컬스 엘엘씨 filed Critical 투 파마슈티컬스 엘엘씨
Publication of KR20180130544A publication Critical patent/KR20180130544A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187031360A 2016-03-28 2017-03-28 위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법 Ceased KR20180130544A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313882P 2016-03-28 2016-03-28
US62/313,882 2016-03-28
PCT/IL2017/050388 WO2017168422A1 (en) 2016-03-28 2017-03-28 Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Publications (1)

Publication Number Publication Date
KR20180130544A true KR20180130544A (ko) 2018-12-07

Family

ID=58579244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031360A Ceased KR20180130544A (ko) 2016-03-28 2017-03-28 위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법

Country Status (11)

Country Link
US (2) US20190091198A1 (https=)
EP (1) EP3436001A1 (https=)
JP (1) JP2019510060A (https=)
KR (1) KR20180130544A (https=)
AU (1) AU2017242161A1 (https=)
BR (1) BR112018069860A2 (https=)
CA (1) CA3018951A1 (https=)
IL (1) IL261799A (https=)
MX (1) MX2018011392A (https=)
WO (1) WO2017168422A1 (https=)
ZA (1) ZA201807098B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019130215A1 (en) * 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
CA3087269A1 (en) 2018-01-10 2019-07-18 Brightseed, Inc. Method for modulating metabolism
WO2019159185A1 (en) * 2018-02-19 2019-08-22 To Pharmaceuticals Llc Compositions and methods for the treatment of protein energy wasting
CA3113724A1 (en) * 2018-09-28 2020-04-02 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
WO2020123383A1 (en) * 2018-12-10 2020-06-18 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
US10993928B2 (en) 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
WO2020219829A1 (en) * 2019-04-26 2020-10-29 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
CN114929033A (zh) * 2019-07-29 2022-08-19 布莱特西德公司 改善消化健康的方法
WO2021113261A1 (en) * 2019-12-02 2021-06-10 Natural Extraction Systems, LLC Compositions comprising novel cannabinoid and terpene profiles
BR112022010335A2 (pt) * 2020-01-08 2022-08-16 Nestle Sa Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinais
WO2021248207A1 (en) * 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
AU2022324615A1 (en) 2021-08-04 2024-02-15 Demeetra Agbio, Inc. Cannabinoid derivatives and their use
WO2023060323A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Terpene-containing formulations and use thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
US20140245495A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named midnight
US20140259228A1 (en) 2013-02-25 2014-09-11 Ytzchak Cohen Cannabis plant named 'avidekel'
US20140245494A1 (en) 2013-02-25 2014-08-28 Ytzchak Cohen Cannabis plant named erez

Also Published As

Publication number Publication date
AU2017242161A1 (en) 2018-11-01
US20190091198A1 (en) 2019-03-28
US20200397743A1 (en) 2020-12-24
JP2019510060A (ja) 2019-04-11
MX2018011392A (es) 2019-07-08
EP3436001A1 (en) 2019-02-06
CA3018951A1 (en) 2017-10-05
BR112018069860A2 (pt) 2020-11-03
WO2017168422A1 (en) 2017-10-05
ZA201807098B (en) 2020-01-29
IL261799A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
KR20180130544A (ko) 위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법
US12239680B2 (en) Sleep disorder compositions and treatments thereof
Biegert et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials.
CN115209882A (zh) 用大麻二酚与依维莫司治疗结节性硬化复合症的方法
CN111263638A (zh) 用于治疗自闭症的组合物和方法
GB2479153A (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
WO2020188568A1 (en) Methods and compositions for treating autism spectrum disorder and associated disorders
WO2020183456A1 (en) Cannabinoid combinations for treating chronic pain in dialysis patients
JP5956868B2 (ja) ロキソプロフェン及びペパーミント抽出物を含有する頻尿治療用組成物
EP4161550A1 (en) Shan-zha for the treatment of depression and anxiety disorders
US11285178B2 (en) Fertilized egg isolate and uses thereof
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
KR20250079154A (ko) 소아 신경계 장애의 치료 방법
WO2025137604A1 (en) Cannabinoid compositions for treatment of complex regional pain syndrome
KR20260052075A (ko) 자폐증 및 관련 증상의 치료를 위한 cw1as1의 칸나비노이드 추출물의 조성물
WO2025027091A1 (en) Composition for use in treatment and/or prevention of chronic musculoskeletal pain including chronic low back pain, chronic non-specific low back pain, osteoarthritis or other chronic musculoskeletal pain conditions comprising delta-9-tetrahydrocannabinol and terpenes
WO2025024862A1 (en) Composition of cannabinoid extract of cw1as1 for the treatment of autism and associated symptoms
WO2025137611A1 (en) Cannabinoid compositions for treatment of post-traumatic epilepsy
Ahmed et al. people ages 15 to 64 years reported cannabis use in 2009.
NZ789786A (en) Sleep Disorder Compositions and Treatments Thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

N231 Notification of change of applicant
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000